INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 198 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2019. The put-call ratio across all filers is 1.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $4,251,834 | -35.0% | 229,333 | -61.2% | 0.00% | -33.3% |
Q2 2023 | $6,540,143 | +71260.0% | 591,333 | -13.3% | 0.00% | -40.0% |
Q1 2023 | $9,165 | -24.1% | 682,406 | -30.1% | 0.01% | -28.6% |
Q4 2022 | $12,082 | -99.9% | 976,706 | -23.4% | 0.01% | -36.4% |
Q3 2022 | $17,793,000 | +287.4% | 1,275,449 | +283.5% | 0.01% | +266.7% |
Q2 2022 | $4,593,000 | -42.2% | 332,607 | -31.9% | 0.00% | -25.0% |
Q1 2022 | $7,944,000 | -12.9% | 488,266 | -12.8% | 0.00% | -20.0% |
Q4 2021 | $9,117,000 | +1660.0% | 559,678 | +2056.9% | 0.01% | – |
Q2 2021 | $518,000 | -1.7% | 25,948 | +13.6% | 0.00% | – |
Q1 2021 | $527,000 | -78.8% | 22,833 | -77.3% | 0.00% | -100.0% |
Q4 2020 | $2,487,000 | -72.1% | 100,708 | -28.9% | 0.00% | -90.0% |
Q1 2020 | $8,919,000 | +23.7% | 141,662 | +143.5% | 0.02% | +122.2% |
Q4 2019 | $7,209,000 | +1417.7% | 58,172 | +875.1% | 0.01% | +800.0% |
Q2 2019 | $475,000 | -70.3% | 5,966 | -58.3% | 0.00% | -50.0% |
Q1 2019 | $1,600,000 | +285.5% | 14,307 | +247.3% | 0.00% | +100.0% |
Q4 2018 | $415,000 | -68.7% | 4,119 | -60.8% | 0.00% | -50.0% |
Q3 2018 | $1,327,000 | -79.3% | 10,501 | -86.3% | 0.00% | -75.0% |
Q2 2018 | $6,420,000 | -55.6% | 76,509 | -67.5% | 0.01% | -57.9% |
Q1 2018 | $14,468,000 | +183.2% | 235,180 | +168.9% | 0.02% | +171.4% |
Q4 2017 | $5,109,000 | -0.9% | 87,461 | -1.5% | 0.01% | -12.5% |
Q3 2017 | $5,155,000 | -77.5% | 88,819 | -53.2% | 0.01% | -80.5% |
Q2 2017 | $22,953,000 | +761.6% | 189,583 | +704.9% | 0.04% | +720.0% |
Q1 2017 | $2,664,000 | -53.7% | 23,554 | -55.6% | 0.01% | -58.3% |
Q4 2016 | $5,758,000 | -78.8% | 53,000 | -67.9% | 0.01% | -73.3% |
Q3 2016 | $27,179,000 | +138.1% | 165,128 | +106.4% | 0.04% | +73.1% |
Q2 2016 | $11,414,000 | -80.0% | 80,000 | -82.0% | 0.03% | -81.7% |
Q1 2016 | $57,075,000 | +5920.6% | 444,271 | +6896.4% | 0.14% | +7000.0% |
Q4 2015 | $948,000 | -83.7% | 6,350 | -81.9% | 0.00% | -81.8% |
Q3 2015 | $5,805,000 | +59.3% | 35,000 | +131.9% | 0.01% | +57.1% |
Q2 2015 | $3,644,000 | -96.9% | 15,095 | -96.4% | 0.01% | -96.8% |
Q1 2015 | $116,692,000 | +35.2% | 413,772 | -25.2% | 0.22% | +18.6% |
Q4 2014 | $86,317,000 | -9.8% | 553,313 | +36.8% | 0.18% | -24.4% |
Q3 2014 | $95,720,000 | +478.1% | 404,412 | +477.9% | 0.24% | +437.8% |
Q2 2014 | $16,559,000 | -66.2% | 69,980 | -52.8% | 0.04% | -68.3% |
Q1 2014 | $48,922,000 | +79.8% | 148,341 | -62.8% | 0.14% | +65.1% |
Q4 2013 | $27,211,000 | +31.2% | 398,527 | +32.6% | 0.09% | +28.4% |
Q3 2013 | $20,743,000 | +204.1% | 300,486 | +97.6% | 0.07% | +219.0% |
Q2 2013 | $6,820,000 | – | 152,094 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |